GB8531071D0
(en)
*
|
1985-12-17 |
1986-01-29 |
Boots Co Plc |
Therapeutic compound
|
CA2138998A1
(fr)
*
|
1992-06-23 |
1994-01-06 |
James W. Young |
Compositions et methodes de traitement de la depression et d'autres troubles, qui contiennent de la sibutramine optiquement pure (-)
|
AU721924B2
(en)
*
|
1992-06-23 |
2000-07-20 |
Sepracor, Inc. |
Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
|
GB9301192D0
(en)
|
1993-06-09 |
1993-06-09 |
Trott Francis W |
Flower shaped mechanised table
|
US5459164A
(en)
*
|
1994-02-03 |
1995-10-17 |
Boots Pharmaceuticals, Inc. |
Medical treatment
|
DE19518988A1
(de)
*
|
1995-05-29 |
1996-12-05 |
Basf Ag |
Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
|
GB9619757D0
(en)
|
1996-09-21 |
1996-11-06 |
Knoll Ag |
Chemical process
|
GB9619961D0
(en)
*
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
GB9619962D0
(en)
*
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
GB9727131D0
(en)
|
1997-12-24 |
1998-02-25 |
Knoll Ag |
Therapeutic agents
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6476078B2
(en)
*
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
US6046242A
(en)
*
|
1998-11-27 |
2000-04-04 |
Basf Aktiengesellschaft |
Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
|
US6323242B1
(en)
|
1998-12-02 |
2001-11-27 |
Peter Sterling Mueller |
Treatment of disorders secondary to organic impairments
|
US6696495B2
(en)
*
|
1998-12-02 |
2004-02-24 |
Snowden Pharmaceuticals, Llc |
Treatment of disorders secondary to organic impairments
|
BG65170B1
(bg)
*
|
1999-03-17 |
2007-05-31 |
Knoll Gmbh |
Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
|
US6552087B1
(en)
|
1999-03-19 |
2003-04-22 |
Abbott Gmbh & Co. Kg |
Therapeutic agent comprising (+)-sibutramine
|
ATE294573T1
(de)
*
|
1999-03-19 |
2005-05-15 |
Abbott Gmbh & Co Kg |
Verwendung von sibutramin oder dessem derivat zur behandlung von schlafstörungen
|
AU3757200A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Gmbh |
Treatment of pulmonary hypertension
|
WO2000056309A1
(fr)
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Procede de traitement de troubles de la sexualite
|
US6803387B1
(en)
|
1999-03-19 |
2004-10-12 |
Abbott Gmbh & Co. Kg |
Treatment of neuropathic pain or fibromyalgia
|
EP1162965A1
(fr)
*
|
1999-03-19 |
2001-12-19 |
Knoll Pharmaceutical Company |
Procede de lutte contre le gain de poids associe a des medicaments therapeutiques
|
US6376551B1
(en)
|
1999-03-19 |
2002-04-23 |
Knoll Pharmaceutical Company |
Treatment of chronic fatigue syndrome
|
AU3760600A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Treatment of orthostatic hypotension
|
AU3895400A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Control of metabolism
|
HUP0200500A2
(en)
*
|
1999-03-19 |
2002-08-28 |
Knoll Gmbh |
Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for aiding weight loss after pregnancy
|
AU3899100A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Treatment of hyperactivity disorders
|
MXPA01009462A
(es)
*
|
1999-03-19 |
2004-03-19 |
Knoll Gmbh |
Tratamiento de calculos biliares.
|
EP1178789B1
(fr)
*
|
1999-03-19 |
2008-07-16 |
Abbott GmbH & Co. KG |
Traitement des troubles de l'alimentation
|
CZ20013284A3
(cs)
*
|
1999-03-19 |
2002-10-16 |
Knoll Gmbh |
Farmaceutická kompozice pro léčbu osteoartritidy nebo dny
|
WO2000056308A1
(fr)
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Prevention de maladies cardio-vasculaires
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
GB9926251D0
(en)
*
|
1999-11-06 |
2000-01-12 |
Knoll Ag |
Pharmaceutical formulation
|
GB0004003D0
(en)
*
|
2000-02-22 |
2000-04-12 |
Knoll Ag |
Therapeutic agents
|
WO2002019998A2
(fr)
*
|
2000-09-08 |
2002-03-14 |
Eli Lilly And Company |
Traitement des prises de poids associees a l'utilisation d'antipsychotiques atypiques
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
WO2002083631A1
(fr)
*
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
|
US20030139386A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Sophie Cote |
Pharmaceutical compositions based on azetidine derivatives
|
CA2478183C
(fr)
*
|
2002-03-12 |
2010-02-16 |
Merck & Co. Inc. |
Amides substitues
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
US20040122033A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20050131074A1
(en)
*
|
2003-08-04 |
2005-06-16 |
Beckman Kristen M. |
Methods for treating metabolic syndrome
|
CA2551037A1
(fr)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de piperidine
|
WO2005097127A2
(fr)
|
2004-04-02 |
2005-10-20 |
Merck & Co., Inc. |
Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
|
WO2006073292A1
(fr)
|
2005-01-06 |
2006-07-13 |
Cj Corporation |
Sels d'acide inorganique de sibutramine
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
BRPI0610580B8
(pt)
|
2005-05-30 |
2021-05-25 |
Banyu Pharma Co Ltd |
composto derivado de piperidina
|
WO2007018248A1
(fr)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
Composé de pyridone
|
DE602006017712D1
(de)
|
2005-08-24 |
2010-12-02 |
Banyu Pharma Co Ltd |
Phenylpyridonderivat
|
US20090264426A1
(en)
|
2005-09-07 |
2009-10-22 |
Shunji Sakuraba |
Bicyclic aromatic substituted pyridone derivative
|
US20090203738A1
(en)
*
|
2005-09-22 |
2009-08-13 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia
|
US8293900B2
(en)
|
2005-09-29 |
2012-10-23 |
Merck Sharp & Dohme Corp |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
US8911751B2
(en)
*
|
2005-10-11 |
2014-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions for nasal delivery
|
CA2625416A1
(fr)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combinaison de composes organiques
|
EP1944301A4
(fr)
|
2005-10-27 |
2012-01-04 |
Msd Kk |
Nouveau derive de benzoxathiine
|
JP4371164B2
(ja)
|
2005-11-10 |
2009-11-25 |
萬有製薬株式会社 |
アザ置換スピロ誘導体
|
RU2455981C2
(ru)
*
|
2006-06-16 |
2012-07-20 |
Теракос, Инк. |
Лечение ожирения антагонистами мускаринового рецептора м1
|
US8748419B2
(en)
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
US20100179131A1
(en)
|
2006-09-07 |
2010-07-15 |
Nycomed Gmbh |
Combination treatment for diabetes mellitus
|
BRPI0716952A2
(pt)
|
2006-09-15 |
2013-10-29 |
Reviva Pharmaceuticals Inc |
Composto, métodos para tratar e/ou prevenir obesidade ou indicação co-mórbida relacionada à obesidade, e para sintetizar derivado de cicloalquilmetilamina
|
CA2664113C
(fr)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
|
WO2008047544A1
(fr)
|
2006-09-28 |
2008-04-24 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé diarylcétimine
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
MX2009010925A
(es)
*
|
2007-04-09 |
2009-11-02 |
Scidose Llc |
Combinaciones de estatinas y agente anti-obesidad.
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
PT2152663E
(pt)
|
2007-06-04 |
2014-06-03 |
Univ Ben Gurion |
Compostos de triarilo e composições que compreendem os mesmos
|
CA2688161C
(fr)
|
2007-06-04 |
2020-10-20 |
Kunwar Shailubhai |
Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
|
CA2714617A1
(fr)
|
2008-03-06 |
2009-09-11 |
Banyu Pharmaceutical Co., Ltd. |
Derive d'alkylaminopyridine
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
EP2301936A1
(fr)
|
2008-06-19 |
2011-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé de spirodiamine-diarylcétoxime
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
JPWO2010013595A1
(ja)
|
2008-07-30 |
2012-01-12 |
Msd株式会社 |
5員−5員又は5員−6員縮環シクロアルキルアミン誘導体
|
WO2010047982A1
(fr)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
|
CA2741672A1
(fr)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
|
WO2010065889A2
(fr)
*
|
2008-12-06 |
2010-06-10 |
Auspex Pharmaceutical |
Inhibiteurs cyclobutaneméthanamine de la réabsorption de monoamine
|
WO2010075068A1
(fr)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Dérivés de pyridopyrimidine et leurs procédés d'utilisation
|
WO2010075069A1
(fr)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
|
WO2011106273A1
(fr)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques
|
WO2012003501A2
(fr)
|
2010-07-02 |
2012-01-05 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthèse et procédés d'utilisation de dérivés de cycloalkylméthylamine
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EA025380B1
(ru)
|
2011-02-25 |
2016-12-30 |
Мерк Шарп Энд Домэ Корп. |
Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
|
KR20150036245A
(ko)
|
2012-08-02 |
2015-04-07 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병 트리시클릭 화합물
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
WO2014139388A1
(fr)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
|
EP2970384A1
(fr)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
WO2015051496A1
(fr)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Composés tricycliques antidiabétiques
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
CN113121450A
(zh)
|
2014-08-29 |
2021-07-16 |
Tes制药有限责任公司 |
α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
|
BR112019007543A2
(pt)
|
2016-10-14 |
2019-07-02 |
Tes Pharma S R L |
inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
AR117122A1
(es)
|
2018-11-20 |
2021-07-14 |
Tes Pharma S R L |
INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
|